None

G-BA: Benlysta offers additional benefit

Germany's Federal Joint Committee (G-BA) said Benlysta belimumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) provides a "significant" degree of additional benefit over "optimized standard therapy" in...

Table: ASMR/IQWiG ratings

Rating innovation ASMR/IQWiG ratings While reimbursement consultants say France's Haute Autorite de Sante (HAS) is more predictable than Germany's Institute for Quality and Efficiency in Health Care (...

Table: IQWiG's matrix

Rating innovation IQWiG's matrix Germany's Institute for Quality and Efficiency in Health Care (IQWiG) developed a matrix to quantify a drug's level of additional benefit vs. a comparator. The table s...

Benlysta: G-BA überstimmt IQWiG

Eine bemerkenswerte Wende: dem Antikörper-Medikament Benlysta wurde ein beträchtlicher Zusatznutzen...

IQWiG updating document to reflect current practice

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) published draft revisions that would update the methods document describing the institute's legal and scientific procedures to refl...

DRI buys Biogen's Benlysta royalties

Biogen Idec has sold its royalty stream for lupus drug Benlysta (belimumab) to DRI Capital in exchange for larger payments over a shorter period which "allows us to accelerate payments that would othe...

IQWiG revising legal, scientific procedures

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said it will partially revise the methods document describing its legal and scientific procedures. The institute expects to publish...

GSK seeks to expand use of Benlysta drug beyond lupus

LONDON, April 3 (Reuters) - GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disor...

Questions on randomised trials by Dionigi and coworkers.

Presenting Germany's drug pricing rule as a cost-per-QALY rule.

In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness...

Belimumab and the Clinical Data.

Benlysta (belimumab) is a fully human recombinant monoclonal IgG antibody that neutralizes soluble B-lymphocyte stimulator and inhibits its biologic activity. Benlysta was recently approved by the US...

Belimumab (Benlysta) for Systemic lupus eruthematosus.

Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods.